There are currently 2668 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
NCT06815991
Recruiting
This is a single center, open label (i.e. participants and study staff will not be masked to the intervention) single ascending dose study to evaluate the safety, tolerability, pharmaokinetics and pharmacodynamics of MIB-725 in community dwelling, healthy adults. Up to 4 successive groups (cohorts) of 8 subjects each will be enrolled in this trial. This study will determine the safety and tolerability of orally administered single ascending (increasing) doses (100, 200, 400, and 800 mg) of MIB-... Read More
Gender:
ALL
Ages:
Between 19 years and 60 years
Trial Updated:
02/18/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Healthy Adults
Register for Updates
High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study
NCT05740839
Recruiting
The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors. The names of the study interventions involved in this study are/is: * High-Intensity Interval Training (HIIT)
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
02/18/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pediatric Brain Tumor
Register for Updates
The Autism Biomarkers Consortium for Clinical Trials: Confirmation Study
NCT05294705
Recruiting
This is a multicenter longitudinal study that aims to validate a set of measures that were previously identified as promising candidate biomarkers and/or sensitive and reliable objective measures of social function in ASD for potential use in clinical trials. The confirmation study will repeat the data collection and analysis protocols from the original ABC-CT study. This confirmation study will recruit 200 ASD and 200 TD comparison participants who are 6-11 years old, matching the overall sampl... Read More
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
02/18/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Autism Spectrum Disorder
Register for Updates
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/18/2025
Locations: Boston Children's Hospital: Department of Immunology, Boston, Massachusetts
Conditions: Asthma
Register for Updates
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
NCT06839469
Recruiting
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
02/17/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
Register for Updates
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NCT04620187
Recruiting
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Salivary Gland Cancer, HER2 Gene Mutation
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
NCT06431594
Recruiting
The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: GSK Investigational Site, Boston, Massachusetts +1 locations
Conditions: Solid Tumors, Neoplasms
Register for Updates
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
NCT03875716
Recruiting
This research study is studying lowering the standard dose of radiation and chemotherapy after surgery, to minimize the side effects and improve the quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Head and Neck Cancer
Register for Updates
Improving Social Relationships for Adolescents with Central Disorders of Hypersomnolence
NCT06251063
Recruiting
The goal of this study is to test a web-based psychoeducational resource for adolescents with central disorders of hypersomnolence and their families. The investigators hope to assess the website's usability, acceptability, and feasibility, as well as its potential effect on social relationship health. Participants will be asked to review the content of the psychoeducational websites. The participants will then provide feedback on the website, as well as the adolescent's social relationships an... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
02/16/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
Recruiting
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: NSCLC, SCLC, DLBCL, NSCLC With High or Low L-MYC or N-MYC Expression, High Grade Neuroendocrine Cancer, L-MYC and N-MYC Amplified Solid Tumors, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, Boston, Massachusetts
Conditions: Social Anxiety Disorder
Register for Updates
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion
NCT04655404
Recruiting
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Register for Updates